Riskpilot← Back to searchSign inGet full accessESTETISK MEDITECH AS
ASActiveOrg 995366444Oredalsveien 134, 1613 FredrikstadWholesale of pharmaceutical and medical goods · NACE 4646Est. 20101 employees
Revenue 2024
NOK 90K
-61% vs 2023
EBITDA margin
-42.7%
-161% vs 2023
Equity ratio
93.7%
Financial strength
Net profit 2024
NOK 25K
+220% vs 2023
| Revenue | NOK 90K | -61% |
| EBITDA | NOK -38K | -161% |
| Net profit | NOK 25K | +220% |
| Total assets | NOK 1,3M | +1% |
| Equity | NOK 1,3M | +2% |
| Employees | 1 | — |
Legal name
ESTETISK MEDITECH AS
Org number
995366444
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
7. april 2010
Share capital
NOK 100 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Utgår
Company purpose
Engroshandel med sykepleie- og apotekvarer.
Address
Oredalsveien 134, 1613 Fredrikstad
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 57 | 113 | 13 | 73 | 33 | 1 163 | 2 857 | 5 310 | 8 210 | 3 633 | 2 512 | 685 | 232 | 90 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −104 | −10 | −0 | −0 |
| EBITDA | −7 | −35 | 30 | −31 | 56 | −81 | 506 | 415 | 310 | 809 | 381 | 931 | 226 | 62 | −38 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −31 | −56 | −85 | −282 | −240 | −212 | −171 | −63 | −0 |
| EBIT | −7 | −35 | 30 | −31 | 56 | −81 | 475 | 359 | 225 | 527 | 141 | 719 | 54 | −0 | −38 |
| Net financials | −0 | −0 | −1 | −1 | −1 | 1 | −1 | −10 | −32 | −99 | −56 | 4 | 32 | −14 | 58 |
| Profit before tax | −7 | −35 | 29 | −31 | 55 | −80 | 475 | 349 | 193 | 428 | 85 | 723 | 87 | −15 | 20 |
| Tax | −2 | −10 | 8 | −8 | 15 | −0 | 98 | 83 | 43 | 94 | 19 | 159 | 15 | 6 | −5 |
| Net profit | −5 | −25 | 21 | −23 | 40 | −80 | 377 | 266 | 150 | 333 | 66 | 564 | 72 | −21 | 25 |
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 114 | 84 | 119 | 99 | 128 | 29 | 806 | 1 336 | 1 684 | 2 041 | 1 436 | 1 755 | 1 506 | 1 333 | 1 343 |
| Equity | 95 | 70 | 90 | 68 | 107 | 27 | 404 | 669 | 819 | 853 | 619 | 1 183 | 1 255 | 1 234 | 1 259 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 33 | 23 | 0 | 235 | 187 | 139 | 0 | 0 |
| Short-term debt | 19 | 15 | 28 | 31 | 21 | 2 | 391 | 633 | 842 | 1 188 | 583 | 386 | 112 | 99 | 85 |
| Total debt | 19 | 15 | 28 | 31 | 21 | 2 | 402 | 666 | 865 | 1 188 | 818 | 573 | 252 | 99 | 85 |
EBITDA margin
-42.7%
This company
15.8%
Market median
-370% vs market
20102024
Equity ratio
93.7%
This company
38.2%
Market median
+145% vs market
20102024
Return on equity
2.0%
This company
18.4%
Market median
-89% vs market
20102024
Net profit margin
27.5%
This company
8.1%
Market median
+240% vs market
20102024
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20102024
Debt / equity
0.07×
This company
0.62×
Market median
+89% vs market
20102024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
DH Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
BE Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Focus Pharma As | Company | 50.0% | 50.0% | 2024 |
Estetisk Meditech As | Company | 50.0% | 50.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Focus Pharma As
ESTETISK MEDITECH AS Board members of ESTETISK MEDITECH AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dag Håkestad Jensen | Chief Executive Officer | 0 companies |
| Bjørn Erik Bergseng | Chief Executive Officer | 0 companies |
| Heidi Engebretsen Bergseng | Chairman | 0 companies |